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Abstract
Background: Cholesteryl ester transfer protein (CETP) is a plasma protein that mediates the exchange of triglycerides
for esterified cholesterol between HDL and apoB-lipoproteins. Previous studies suggest that CETP may modify
glucose metabolism in patients or cultured cells. In this study, we tested if stable CETP expression would impair
glucose metabolism.
Methods: We used human CETP transgenic mice and non-transgenic littermate controls (NTg), fed with control
or high fat diet, as well as in dyslipidemic background and aging conditions. Assays included glucose and insulin
tolerance tests, isolated islets insulin secretion, tissue glucose uptake and adipose tissue GLUT mRNA expression.
Results: CETP expression did not modify glucose or insulin tolerance in all tested conditions such as chow and
high fat diet, adult and aged mice, normo and dyslipidemic backgrounds. Fasting and fed state plasma levels of
insulin were not differ in CETP and NTg mice. Direct measurements of isolated pancreatic islet insulin secretion
rates induced by glucose (11, 16.7 or 22 mM), KCl (40 mM), and leucine (10 mM) were similar in NTg and CETP
mice, indicating that CETP expression did not affect β-cell function in vivo and ex vivo. Glucose uptake by insulin
target tissues, measured in vivo using 3H-2-deoxyglucose, showed that CETP expression had no effect on the
glucose uptake in liver, muscle, perigonadal, perirenal, subcutaneous and brown adipose tissues. Accordingly,
GLUT1 and GLUT4 mRNA in adipose tissue were not affected by CETP.
Conclusions: In summary, by comparing the in vivo all-or-nothing CETP expressing mouse models, we demonstrated
that CETP per se has no impact on the glucose tolerance and tissue uptake, global insulin sensitivity and beta cell
insulin secretion rates.
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Background
Type 2 Diabetes mellitus (T2DM) is a metabolic dis-
order characterized by high glucose plasma levels and
insulin resistance [1]. Insulin resistant diabetic patients
commonly present dyslipidemia, which is generally char-
acterized by high triglycerides and low HDL plasma
levels [2]. The HDL-cholesterol level is recognized as a
protective factor against atherosclerosis and cardiovascu-
lar diseases because HDL promotes reverse cholesterol
transport from the periphery to the liver and acts as
anti-inflammatory, antioxidant and anti-thrombotic lipo-
protein [3].
Cholesteryl ester transfer protein (CETP) is a plasma
protein that mediates the exchange of triglycerides from
apoB-lipoproteins for esterified cholesterol from HDL
[4]. In this way, CETP promotes reduction of plasma
HDL-cholesterol and, thus, may increase the risk of ath-
erosclerosis. Therefore, in the last decades, efforts have
been made to inhibit CETP activity as an anti-
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atherogenic intervention. Although these CETP inhibi-
tors increase HDL-cholesterol and decrease LDL-
cholesterol concentrations, they failed to prove their bene-
fits in reducing cardiovascular disease mortality [5–7].
There are evidences that suggest a relationship be-
tween CETP and glucose homeostasis, although this
issue has been a matter of debate. Clinical studies associ-
ated higher CETP levels to T2DM risk [8] and showed
that CETP polymorphism may modulate insulin sensitiv-
ity [9, 10]. Individuals with higher CETP mass present
higher values of fasting insulin and HOMA insulin re-
sistance index compared with individuals with lower
CETP mass. A post-hoc analysis of the ILLUMINATE
trial linked CETP inhibition by torcetrapib to a signifi-
cant improvement in glycemic control [11].
On the other hand, comparison of subject groups with
distinct insulin sensitivity (lean vs. obese and rested vs.
exercised) found no association between CETP and insu-
lin sensitivity [12]. In addition, through a genome-wide
approach, Sladek et al. [13] performed a systematic
search looking for associations between T2DM risk and
almost 400,000 polymorphisms. They did not find any
significant associations between major genes or proteins
associated with HDL metabolism and risk of T2DM or
glucose intolerance. Furthermore, a recent clinical trial
using a potent CETP inhibitor, dalcetrapib, failed to im-
prove insulin sensitivity in patients [14].
In the opposite direction, Ju et al. [15] found that ex-
pressing human CETP in 3T3-L1 cells resulted in in-
creased glucose uptake, suggesting that CETP expression
would improve insulin sensitivity. Accordingly, Cappel
et al. [16] reported that simian CETP expression pro-
tects against insulin resistance in obese female mice.
In light of these conflicting evidences of the role of
CETP on the glucose and insulin homeostasis, we took
the advantage of the human CETP transgenic mice
model, expressing physiological levels of CETP, and
compared them with their CETP non-expressing litter-
mate controls to further investigate this issue.
Results
Human CETP transgenic mice were used to verify the
effects of CETP long-term expression over glucose me-
tabolism. Heterozygous CETP transgenic (CETP-Tg)
mice expressing a human natural promoter-driven CETP
transgene [17] were compared to their non-transgenic
littermates mice. These CETP transgenic mice present
human like plasma levels of CETP (~2 ug/ml) [18],
modest reductions of HDL-cholesterol plasma levels
[19], authentic tissue pattern of expression and regula-
tion of gene expression [17, 20].
As shown in Fig. 1, the glycemic curves after a glucose
load (GTT) in female (Fig. 1a) and male (Fig. 1b) mice
and after an insulin load (ITT) were similar between
CETP and NTg mice. Therefore, CETP expression ap-
parently does not modify either glucose tolerance or in-
sulin sensitivity. To confirm these results, we also
measured plasma insulin levels in both fasting and fed
states in male and female mice (Table 1) and found no
effects of CETP expression on the insulinemia. Next we
evaluated the ex vivo insulin secretion by isolated pan-
creatic islets stimulated by several secretagogues (Fig. 2).
Glucose (11 mM or 16.7 mM), KCl (40 mM), and leu-
cine (10 mM) induced insulin secretion in a similar
manner in islets isolated from NTg or CETP mice, indi-
cating that CETP expression does not affect β-cell
function.
Tissue specific sensitivity to insulin was directly deter-
mined in vivo by measuring glucose uptake by white
(WAT) and brown (BAT) adipose tissues, liver and
muscle after a bolus ip injection of 3H-2-deoxiglucose
(3H-2DG) dissolved in a glucose solution (2 g/Kg BW).
As shown in Fig. 3, CETP expression had no effects on
the glucose tissue uptake when compared to NTg mice,
as well as it did not modify the plasma clearance of 3H-
2DG and glucose levels. Since a previous study [15] re-
ported that 3T3 mouse adipocytes transfected with
CETP cDNA presented increased glucose uptake, we
checked the expression of genes encoding the glucose
transporters GLUT1 (Scl2a1) and GLUT4 (Scl2a4)
mRNA levels in the mice adipose tissue (Fig. 4). In
agreement with the results of in vivo glucose uptake,
CETP expression did not change GLUT gene expression
in the adipose tissue depots.
To further investigate if CETP would affect glucose
metabolism in the presence of other metabolic compli-
cations, glucose tolerance tests were performed in aged
or dyslipidemic backgrounds. For this purpose, we
crossbred CETP mice with a model of hypertriglyc-
eridemia due to overexpression of apolipoprotein CIII
(CETP+/−/CIII−/+) and with a model of hypercholester-
olemia due to the disruption of the LDL receptor gene
(CETP+/−/LDLr−/+). These crosses were previously
studied and exhibit marked hypertriglyceridemia and
mild hypercholesterolemia, respectively [21, 22]. Table 2
shows that CETP expression had no effect on the glu-
cose tolerance in male aged (18 month old), hypertri-
glyceridemic (apoCIII overexpressing) or LDL receptor
defective mice. In addition, possible effects of CETP on
glucose homeostasis were also investigated in the con-
text of a high fat diet (60 % Kcal as saturated fat) for
3 months. As shown in Fig. 5, CETP expression did not
affect glucose tolerance (Fig. 5a), insulin sensitivity (Fig. 5b)
and islet insulin secretion (Fig. 5c) in high fat fed mice. As
expected, insulin secretion was higher in all mice fed with
a high fat diet compared to chow diet. However, the com-
parison between NTg and CETP mice showed no signifi-
cant differences in insulin secretion (Fig. 5c).
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Discussion
Several previous studies have suggested a relationship
between CETP and glucose metabolism [8–10, 15, 16]
including a putative positive effect of pharmacological
inhibition of CETP on the glycemic control [11, 23].
Thus, in this study we used mice expressing a human
CETP gene to investigate the long-term consequences of
CETP on the glucose homeostasis. Because wild type
mice do not express this gene [24], CETP transgenic
mice are useful to explore CETP effects in a complex
in vivo biological system. We investigated the main steps
of glucose homeostasis and verified that CETP expres-
sion causes no significant alterations in glucose toler-
ance, fasting and fed plasma insulin levels, global insulin
sensitivity, pancreatic islet insulin secretion and glucose
tissue uptake. Previous data from our group had already
shown no differences in the plasma levels of glucose and
insulin, either in fasted or fed state, in CETP transgenic
compared to NTg mice [25]. Therefore, according to our
data, the CETP expression does not impose any disad-
vantage for glucose homeostasis maintenance.
Ju et al. have previously shown that in vitro human
CETP expression in adipocyte 3T3-L1 mouse cell
line (driven by a heterologous viral promoter) re-
sulted in enhanced insulin-mediated glucose uptake
[15]. Here, we demonstrate that in vivo human CETP
expression driven by its natural promoter did not
affect glucose uptake by adipose and other insulin
target tissues. It is likely that the in vivo hormonal
milieu present in the whole organism are responsible
for these distinct results.
Briand et al. [26] demonstrated in hamsters that CETP
inhibition by torcetrapib treatment significantly re-
duced blood glucose and plasma insulin levels after a
high fat/high cholesterol diet. 3H-2DG uptake was re-
duced in adipose tissues but increased in soleus, liver
and heart of these torcetrapib treated hamsters. How-
ever, the pattern of CETP tissue expression in hamsters
markedly differs from that observed in the transgenic
mice, which is similar to humans [17, 27]. Contrary to
the effect observed in hamsters, torcetrapib treatment
of humans induced an increase in post-prandial plasma
insulin levels [23].
Fig. 1 CETP expression does not affect either glucose tolerance or insulin sensitivity. Glucose tolerance test (GTT) was performed in 5–9 month
old NTg and CETP female (a: oral GTT) (n = 8 each group) and male (b: ip GTT) (n = 5 each group) mice, fasted for 12 h. lntraperitoneal (ip)
insulin-tolerance test (ITT) was performed in fed mice (c) (NTg: n = 2 male and 2 female, CETP: n = 2 male and n = 3 female). Values are expressed
as mean ± SE. Student’s t test: non-significant
Table 1 CETP expression has no effect on insulin plasma levels
Plasma insulin (ng/ml)
NTg CETP
Female Fast 0.330 ± 0.023 (9) 0.380 ± 0.040 (5)
Fed 0.488 ± 0.082 (9) 0.970 ± 0.604 (5)
Male Fast 0.240 ± 0.108 (3) 0.447 ± 0.047 (4)
Fed 0.464 ± 0.024 (3) 0.619 ± 0.066 (4)
Insulin plasma level of male and female CETP expressing mice and their
littermates’ controls in fed state and after 12 h fast. Values are expressed as
mean ± SE (n). Student’s t test: NTg vs. CETP: non-significant
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Cappel et al. [16] used a mouse model expressing a
simian CETP gene under control of a constitutive pro-
moter to demonstrate that CETP expression protects
against diet induced insulin resistance in obese female
mice, but not in male or in chow fed mice. They postu-
late that CETP would increase cholesterol delivery to
the liver, increasing bile acids excretion into the gut.
These effects would initiate signaling pathways that im-
prove insulin sensitivity, such as those observed after an
oral taurodeoxycholic acid treatment [28]. Nevertheless,
the CETP transgenic mice used here present no alter-
ations in bile acids secretion into the bile and fecal ex-
cretion [29]. In addition, bile acids mass excretion is not
altered in torcetrapib-treated hamsters [26].
Siebel et al. [23] showed that plasma post-CETP inhib-
ition promoted glucose-stimulated insulin secretion in
MIN6N8 insulinoma cells that were pretreated with oxi-
dized (ox) LDL. The authors attributed these effects to
the higher concentrations of HDL-cholesterol in the in-
cubation medium rather than to the low CETP levels. In
fact, it was previously shown that oxLDL exerts deleteri-
ous effects on beta cells, such as activation of JNK path-
way and apoptosis, which are countered by HDL
particles [30]. One way by which high HDL-cholesterol
levels would improve the efficiency of insulin secretion
could be through removing cholesterol from the cell
membrane. As previously demonstrated by our group,
both abnormally high or low islet cholesterol content
impairs glucose stimulated insulin secretion, while its
normalization improves it [31, 32]. It is important to
emphasize that CETP expression decreases HDL-
cholesterol levels in a gene dosage manner [19]. The
mouse model used here exhibits about 15–20 % lower
HDL-cholesterol levels when compared with NTg mice
[19, 22]. Even though, here we verified no differences in
insulin secretion of freshly isolated islets from NTg or
CETP mice.
Lopez-Rıos et al. [10] have hypothesized that individ-
uals with higher CETP activity have HDL particles
enriched in triglycerides, which would increase the flux
of free fatty acid to the liver and decrease hepatic sensi-
tivity to insulin, and thus, predispose to diabetes. Ac-
cording to De Vries et al. [8], CETP mass and activity
was higher in T2DM subjects, suggesting that lowering
plasma CETP could ameliorate diabetes-associated car-
diovascular risk. Alongside, Barter et al. [11] reported
that treatment with torcetrapib improves glycemic con-
trol in atorvastatin-treated patients with T2DM. Since
literature shows that CETP have worse outcomes in un-
healthy patients, here CETP effects were also investi-
gated in mice treated with high fat diet, with
hyperlipidemic background, and also in aged mice. How-
ever, our data show no harm of CETP stable expression
even when metabolism was challenged to more adverse
conditions. Since different results were found with CETP
expressing mice and with CETP inhibitor torcetrapib
[11, 23], it is also possible to speculate about a direct ef-
fect of this drug on the glycemic control, independently
of the CETP levels. Our data is in agreement with pre-
vious work that showed that CETP activity does not
correlate with parameters of insulin sensitivity in non-
diabetic individuals [12]. A conciliatory view of most
conflicting clinical and experimental data is that CETP
per se is not relevant to glucose homeostasis/insulin
sensitivity, but actually the HDL-cholesterol levels and
perhaps the HDL functionality is important to regulate
glucose metabolism and modulate diabetes risk [33]. As
mentioned before, the CETP mouse model studied here
present modest changes in HDL plasma levels.
Conclusions
In conclusion, by comparing in vivo all-or-nothing hu-
man CETP mouse model, our data demonstrate that
CETP per se does not modulate glycemic control and in-
sulin secretion in young and aged healthy mice, as well
as in dyslipidemic and high fat fed mice.
Methods
Animals
All experimental protocols were approved by the univer-
sity’s Committee for Ethics in Animal Experimentation
(CEUA/UNICAMP, protocol # 1107-1) and are in ac-
cordance with the “Principles of Laboratory Animal
Care” (NIH publication no. 85–23, revised 1985). In this
study, experiments were performed in 5 to 9 months old
mice (adult), and in an additional aged group of
Fig. 2 CETP expression does not impact on insulin secretion. Freshly
isolated islets from female NTg (white columns) or CETP (gray columns)
mice with 7 month of age were incubated in Krebs bicarbonate buffer
containing 5.6 mmol/l glucose for 30 min at 37 °C (5 islets/well, four
replicates in each condition). Then, the buffer was replaced by fresh
buffer containing 2.8 mM glucose, 2.8 mM glucose plus KCl (40 mM),
2.8 mM glucose plus leucine (10 mM), 11 mM glucose or 16.7 mM
glucose. After 1 h incubation, buffer was collected and insulin was
measured by radioimmunoassay. Insulin release was normalized by
islet number. Values are expressed as mean ± S.E. n = 4–6 mice in 3
independent experiments. Student’s t test: non-significant
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18 months old mice. Both male and female mice were
used for the experiments. Heterozygous CETP trans-
genic (CETP-Tg) mice expressing a human natural
promoter-driven CETP transgene, line 5203 [17] and
non-transgenic littermates mice were used. CETP-Tg
mice were crossbred with human apolipoprotein CIII
transgenic mice, line 3707 [34] to generate apoCIII and
apoCIII/CETP. In addition, LDL receptor (LDLr−/−)
knockout mice [35] and CETP-Tg mice were crossbred
to generate LDLr−/+ and CETP+/−/ LDLr−/+ mice. CETP-
expressing mice were screened by assaying plasma CETP
activity, as previously described [18]. The apoCIII trans-
genic mice had plasma triacylglycerol levels above
300 mg/dL and LDLr−/− mice had plasma cholesterol
levels above 200 mg/dL, whereas the non-transgenic
mice had both triacylglycerol and cholesterol levels
below 100 mg/dL. Mice were housed in a temperature-
controlled room (22 ± 1 °C) on a 12 h light/dark cycle
and had free access to food and water. The chow diet
(Nuvital CR1, Colombo, Brazil) was offered from
weaning and its composition was (% by weight) 23 %
protein, 4.5 % total fat, 33 % carbohydrates and 21 %
fiber, with a total of 263 kcal/100 g. The high fat diet
was offered from 2 to 5 months old and its composition
was (% by weight) 14 % protein, 35 % total fat (59 % of
calories), 41 % carbohydrates and 5 % fiber, with a total
of 536 kcal/100 g.
Blood glucose and plasma insulin levels
Blood glucose concentrations were measured using a glu-
cose analyzer (Accu-Chek Advantage, Roche Diagnostic,
Switzerland). Plasma insulin levels were determined by
ELISA (Ultra Sensitive Mouse Insulin ELISA Kit, Christal
Chem, USA) according to the manufacturer instructions.
Glucose tolerance test (GTT) and insulin tolerance test
(ITT)
Female mice were submitted to an oral glucose tolerance
test after 12 h fast. Basal blood sample was collected
from the tail tip (t = 0 min) and a glucose load of 1.5 g/
Fig. 3 CETP expression has no effect on tissue glucose uptake. Perigonadal, perirenal, subcutanous and brown (BAT) adipose tissue, liver and
muscle glucose uptake was measured in vivo, 15 min and 2 h after an intraperitoneal injection of glucose (2 g/Kg BW) and 3H-2-deoxiglucose
(150 μCi/Kg BW) in 5 month old NTg and CETP female mice (a). Blood was collected 3H activity was determined in plasma (b) and glucose (c) in
blood. Mean ± SE (n = 3–6 per group). Student’s t test: non-significant
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kg body weight was then administered by oral gavage.
Additional blood samples were collected at 15, 30, 60
and 90 min after glucose ingestion. Male mice were
submitted to an intraperitoneal (ip) glucose tolerance
test. After 12 h fast, mice were injected with a glucose
load of 2 g/kg body weight and blood samples were
collected at 0, 15, 30, 60 and 120 min. For the ITT,
blood was taken from fed female and male mice imme-
diately before insulin ip injection [0.75 U/Kg body
weight of human insulin (Human insulin R, Eli Lilly
and Company)] and at the times 10, 15, 30 and 60 min
for glucose analyses.
Pancreatic islet isolation and insulin secretion
The pancreatic islets were isolated from fed mice by col-
lagenase digestion (0.8 mg/mL; Type V; Sigma C9263)
(adapted from [36]), rinsed tree times in Hanks Solution
[137 mmol/l NaCl; 5.4 mmol/l KCl; 0.8 mmol/l
MgSO4.7H20; 0.34 mmol/l Na2HPO4; 0,44 mmol/l
KH2PO4; 1.26 mmol/l CaCl2.2H20; 4.2 mmol/l NaHCO3;
pH 7.4 plus 5.6 mmol/l glucose and 0.1 % (w/v) BSA] to
remove the enzyme from medium and then selected
manually under a microscope to exclude any contamin-
ating tissues. After isolation, batches of 5 islets each
were pre-incubated in Krebs-Ringer bicarbonate buffer
Fig. 4 CETP expression does not affect glucose transporters gene expression in adipose tissues. Scl2a1 (encoding GLUT1) and Scl2a1 (encoding
GLUT4) mRNA expression were determined in visceral (a), subcutaneous (b) and brown (c) adipose tissue depots of 5 months old non-transgenic
(NTg) and CETP female mice. Gene expression was quantified by real-time RT-PCR using the ΔΔCT method normalized to β-actin and then expressed
relative to the control (NTg) group. Mean ± SE (n = 7–12 per group). Student’s t test: non-significant
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(KRBB) containing: 115 mmol/l NaCl, 5 mmol/l KCl,
10 mmol/l NaHCO3, 2.5 mmol/l CaCl2.2H2O, 1 mmol/l
MgCl2.6H2O and 15 mmol/l HEPES, pH 7.4 plus
5.6 mmol/l glucose and 0.3 % (w/v) BSA for 30 min at
37 °C. Then, the buffer was replaced by fresh buffer
containing 2.8 mM glucose, 2.8 mM glucose plus KCl
(40 mM), 2.8 mM glucose plus leucine (10 mM), 11 mM
glucose, 16.7 mM glucose or 22.2 mM glucose. After 1 h
incubation, buffer was collected and insulin was mea-
sured by radioimmunoassay [37] using rat insulin as
standard, human recombinant 125I-Insulin (PerkinElmer)
and anti-insulin from guinea pig. Insulin release was
normalized by islet number.
Glucose tissue uptake (in vivo)
After 12 h fasting, mice were injected (i.p.) with glucose
(2 g/Kg body weight) plus 3H-2-deoxiglucose (150 μCi/
Kg body weight) [38]. Blood sample were collected from
the tail tip before (time 0) and after the injection at 15,
30, 60, 90 e 120 min for glucose and radioactivity deter-
mination. At 15 min and 120 min, groups of mice were
anesthetized and killed by exsanguination. Tissues [liver,
muscle (gastrocnemius + soleus), perigonadal, perirenal,
subcutaneous and brown adipose tissue] were collected,
washed with saline, and digested in a tissue solubilizer
solution (GE Healthcare-Amersham). Non-aqueous cin-
tilation liquid (GE Healthcare-Amersham) were added
Fig. 5 CETP expression does not affect glucose tolerance, insulin sensitivity and secretion in obese mice. Glucose tolerance test performed in NTg
and CETP female mice treated with high fat diet from 2 to 5 months of age, after 12 hs of fasting, n = 5–7 per group (a). lntraperitoneal (ip)
insulin-tolerance test (ITT) was performed after 3 h fasting, n = 6–8 (b). Freshly isolated islets from NTg mice fed with chow diet (black columns),
and NTg (white columns) and CETP (gray columns) mice fed with high fat diet were incubated in the presence of 2.8 mM glucose, 2.8 mM glucose
plus KCl (40 mM), 11 mM glucose or 22.2 mM glucose, as described in Fig. 2, n = 2–4 female mice in two independent experiments (c). Values are
expressed as mean ± S.E. Student’s t test: non-significant
Table 2 CETP expression has no effect on glucose tolerance in
aged, hypertriglyceridemic or hypercholesterolemic mice
Model AUC ± SE n
(mg.dl−1.min) male/female
Aged-NTg 10933 ± 1570 (4) 4/0
Aged-CETP 11737 ± 1069 (7) 7/0
ApoCIII−/+ 22777 ± 3238 (4) 3/1
ApoCIII−/+ /CETP−/+ 25114 ± 9466 (3) 1/2
LDLr−/+ 15920 ± 2587 (4) 0/4
LDLr−/+/CETP+/− 12951 ± 407 (5) 2/3
Area under the curve (AUC) of oral glucose tolerance test in aged (18 month
old), apo CIII transgenic and LDL receptor deficient (LDLr−/+) mice expressing
or not CETP, fasted for 12 h. At time zero, mice received a glucose dose of
1.5 g/kg body weight by gavage. Samples for glucose determination were
collected from the tail tip at 0, 15, 30, 60 and 120 min. Values are expressed as
mean ± SE (n: male and female pooled data). Student’s t test for all
comparisons: non-significant
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to count 3H radioactivity in the samples using a beta-
counter (Bekmam - LS 6000TA). The quench caused by
sample color was corrected by adding 1000 cpm of 3H-
triolein, providing proportional correction.
RNA extraction and real-time RT-PCR
Total RNA from adipose tissue depots were purified
using RNeasy Lipid Tissue Mini Kit (QIAGEN, Germany),
according to the manufacture’s protocol. The integrity of
the RNA was assessed using Tris-borate 1.2 % agarose gels
stained with ethidium bromide. The amount and purity of
the RNA were determined by optical density readings at
260 and 280 nm (Gene Quant, Amersham-Pharmacia
Biotech). Genomic DNA contamination was excluded
by running a PCR on the RNA samples. cDNA was ob-
tained from 2 μg of total RNA by reverse transcription
using an Applied Biosystems kit (High-Capacity cDNA
reverse transcription kit) according to the manufac-
turer’s instructions. mRNA expression was determined
by real-time RT-PCR (Step One Real-time PCR System,
Applied Biosystems, Foster City, CA) using a SybrGreen
PCR Master Mix and the specific primers (Table 3).
Gene expression was quantified using the ΔΔCT
method by measuring the threshold cycle normalized to
β-actin and then expressed relative to the control groups.
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